On Friday, Humana filed a lawsuit in the Eastern District of Pennsylvania, alleging that 37 defendants engaged in a “far-reaching conspiracy” to “blatantly fix the price” of generic drugs.
On Friday, Humana filed a lawsuit in the Eastern District of Pennsylvania, alleging that 37 defendants engaged in a “far-reaching conspiracy” to “blatantly fix the price” of generic drugs.
In the 610-page complaint, Humana says that it is seeking to recover damages incurred from paying overcharges for commonly used generics. Humana alleges that the defendants, including Actavis, Dr. Reddy’s Laboratories, Glenmark, Mylan, Sandoz, Sun, Teva, and others, used secret communications at public and private events—including major trade association meetings—to orchestrate a scheme in which they fixed prices and rigged bids on drugs.
The complaint contains exhibits listing the names of generic companies’ employees who attended the same professional meetings between 2011 and 2016 to support these claims, and the document also contains numerous, partially redacted LinkedIn messages, emails, conference call agendas, and phone records documenting contact between the companies’ employees.
The complaint alleges that the scheme, which divided the market into shares, was known among the defendants as the “rules of engagement,” and resulted in some generic drug prices rising by more than 1000%. The drugs at the heart of the lawsuit include antibiotics, nonsteroidal anti-inflammatory drugs, diabetes treatments, asthma drugs, anticoagulants, cardiovascular drugs, and many others. Some of the drugs listed in the suit, including the sickle cell drug hydroxyurea, and the immunosuppressive drug methotrexate, are World Health Organization-listed essential medicines.
Much of the complaint focuses on Teva, and on the alleged conduct of the company’s director of global generic sourcing, Nisha Patel, who, Humana says, was responsible for identifying on which drugs the company could increase prices. The complaint says that Patel regularly communicated with competitors regarding their willingness to increase prices.
Humana also alleges that many of the defendants have been coordinating to obstruct ongoing investigations into their conduct.
Humana is asking the court for a judgement against the defendants for damages sustained, and for an award punitive damages in an amount to be determined in a trial.
The new lawsuit follows after Humana filed a largely similar, yet less extensive, suit in the same district in 2018.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Study: More Biosimilar Competition Is Not Lowering Patient OOP Costs
March 29th 2024Despite more biosimilars entering the market and generating significant savings for payers and health care systems, these savings are not resulting in lower out-of-pocket (OOP) costs for patients, according to a recent study.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Coherus Biosciences Cites Biosimilars as Main Drivers of 2023 Revenue Growth
March 14th 2024In its earnings report for the fourth quarter and full year of 2023, Coherus Biosciences detailed its rising revenue growth, which it partly attributed to increased sales for its pegfilgrastim and ranibizumab biosimilars.